Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,270
Recruiting: 2,320
Ph III recruiting: 270
Growth YoY: +13.6%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,961)

clinicaltrialsPublishedShowing 101–150 of 1,224 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07459634	A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC	recruiting	Phase 2	50	Jazz PharmaceuticalsINDUSTRY	1	Sep 17, 2026	clinicaltrials
NCT07572864	Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC	recruiting	Phase 2	9	West China HospitalOTHER	1	Sep 17, 2026	clinicaltrials
NCT05155033